ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Of the big oncology deals since 2016, there are still plenty that could go either way.
Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.